Repeated Voluntary Drug Intoxication (IMVr): Characterization of a New Addictive Behavior by Clinical Phenotyping and Functional Imaging
NCT ID: NCT02889042
Last Updated: 2019-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
1 participants
INTERVENTIONAL
2016-07-19
2016-07-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this context it is urgent to make an accurate characterization of these patients IMVr because the integration of the addictive dimension in their care will adapt strategies psychotherapeutic, pharmacological, and the terms of issue of psychotropic and especially benzodiazepines .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Volunteers repeated drug poisoning
performing MRI and a biological assessment
MRI and biological assessment
performing a MRI and a biological assessment
Volunteers single drug poisoning
performing MRI and a biological assessment
MRI and biological assessment
performing a MRI and a biological assessment
alcoholic
performing MRI and a biological assessment
MRI and biological assessment
performing a MRI and a biological assessment
volunteers
performing MRI and a biological assessment
MRI and biological assessment
performing a MRI and a biological assessment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI and biological assessment
performing a MRI and a biological assessment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Man or woman hospitalized (e) in the aftermath of a IMV:
* History of at least 2 for the IMV group IMVr
* First suicide attempt high intentionality (SIS score\> 20/30) for group IMVS
* Man or woman with alcohol dependence according to DSM-IV-TR, in the aftermath of withdrawal (outpatient or inpatient) for the alcohol group
* Man or woman free from any addictive disorder, suicidal or mood for the control group
And all of the following criteria:
* Age greater than or equal to 18 and less than or equal to 60 years
* Informed consent in writing signed by the patient
* Person affiliated to the social security or beneficiary of such a scheme
Exclusion Criteria
* Have a history of scarification or addictive disorder (behavioral or product)
In the alcohol group:
* TS present history
For all patients, presenting at least one of the following criteria:
* Age less than 18 years, over 60 years.
* acute or chronic delusional disorder.
* Cognitive impairment or impeding the reading comprehension quizzes.
* secondary pathologies at a stroke.
* Denial of participation.
* Contraindications to MRI.
* Subjects with clinically significant gastrointestinal, renal, hepatic, endocrine, cardiovascular or respiratory (especially persistent asthma) which can prevent stay of 60 min in MRI without being hindered.
* No participant to another pharmacological study.
* unauthorized treatments: all psychotropic treatments (except anti-anxiety treatments benzodiazepine average duration of action and antihistamine), baclofen and other treatment can modify vasoreactivity fMRI.
* Coagulation disorders against-indicating blood.
* People under guardianship
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
PENNEL Lucie
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Grenoble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Grenoble
Grenoble, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38RC14.182
Identifier Type: -
Identifier Source: org_study_id